Abstract
We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Comis RL. The current situation: Erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005;23:3227–3234.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer. J Clin Oncol 2003;21:2237–2246.
Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previous treated non-small cell lung cancer. N Engl J Med 2005;353:123–132.
Chang JW, Chou CL, Huang SF, Wang HM, Hsieh JJ, Hsu T, et al. Erlotinib response of EGFR-mutant gefitinib-resistant non-smallcell lung cancer. Lung cancer 2007;58:414–417.
Wu SG, Shih JY, Yu CJ, Yang PC. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol 2008;4:451–452.
Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528–2533.
Wong AS, Soong R, Seah SB, Lim SW, Chuah KL, Nga ME, et al. Evidence of disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3:400–404.
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with nonsmall-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513–2520.
Shoji F, Yano T, Yoshino I, Mori D, Yamasaki F, Kohno H, et al. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. Eur J Surg Oncol 2008;34:89–93.
Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50–57.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shoji, F., Kawano, D., Ito, K. et al. Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: Report of a case. Surg Today 41, 255–257 (2011). https://doi.org/10.1007/s00595-009-4259-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-009-4259-3